BioCryst Pharmaceuticals (BCRX) revenue breakdown
By product, Product sales, net is the largest at 71% of fiscal 2025 revenue, growing 112% a year over 8 years.
Revenue by product
Fiscal years, as BioCryst Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $875M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | — | $2M | — | $18M | $3M | $136M | $268M | $325M | $443M | $623M | 71% |
| License and other revenues | — | — | — | — | — | — | — | — | — | $244M | 28% |
| Collaborative and other revenues | $14M | $13M | $15M | $25M | $11M | $21M | $3M | $7M | $8M | $8M | 1% |
| Royalty revenue | $10M | $11M | $6M | $6M | $3M | — | — | — | — | — | — |
| Product | $2M | — | — | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BCRX.
Open BCRX in InvestinglyQuestions
Where does BioCryst Pharmaceuticals make its money?
In fiscal 2025, by product: Product sales, net $623M, License and other revenues $244M, Collaborative and other revenues $8M.
From BioCryst Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.